Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
People in the News at Illumina, Centogene, BioSkryb
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Jan. 30, 2023.
PacBio and Oxford Nanopore sequencers perform well on "easy" genes that have traditionally been sequenced on Illumina machines, as well as on intractable genes.
People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Jan. 23, 2023.
NY Genome Center Team Harnesses Ultima Genomics Platform for High-Sensitivity ctDNA Sequencing
Premium
Taking advantage of the new platform's low sequencing cost, the researchers sequenced cell-free circulating DNA (ccfDNA) in plasma at high depth for sensitive cancer monitoring.
Ravgen NIPT Patents Withstand Illumina Challenge
The US Patent Trial and Appeal Board delivered a pair of rulings stating that Illumina failed to show Ravgen's innovations should be considered unpatentable.